According to new study data presented at the 2024 Pediatric Academic Societies Meeting, dupilumab (dupixent; Sanofi and Regeneron) demonstrated positive safety and efficacy results for up to 1 year in infants and preschool-age children with atopic dermatitis.
Atopic dermatitis (AD) is a prevalent inflammatory skin condition among children, and in individuals with moderate-to-severe disease, there are significant challenges for long-term management. However, a recent study presented at the 2024 Pediatric Academic Societies Meeting has shed light on a promising treatment option for children aged from 6 months to 5 years with moderate-to-severe AD.
In the study, investigators focused on evaluating the efficacy and safety of dupilumab over a period of 1 year in this patient population.
The study (NCT02612454) enrolled children who had participated in the LIBERTY AD PRESCHOOL trial (NCT03346434, part B; parent study), which was a 16-week double-blind phase 3 trial. Dupilumab was administered to participants subcutaneously every 4 weeks, with dosage varying based on the weight of the children.
The results of the study demonstrated significant improvements in various markers of AD severity and quality of life.
Key findings include:
The investigators concluded that up to 1 year of dupilumab treatment provide sustained improvement in AD symptoms and quality of life for children aged 6 months to 5 years with moderate-to-severe disease. Additionally, dupilumab appears to have an acceptable safety profile, offering hope for better management of this challenging condition in young children, according to the investigators.
Reference:
Paller AS, Siegfried EC, Xiao J, Prescilla R, Bansal A. 336 Efficacy of dupilumab in infants and preschoolers with atopic dermatitis up to 1 year. British Journal of Dermatology. 2023;188(Supplement_2):ljac140.030. doi:10.1093/bjd/ljac140.030
Itchy skin associated with sleep problems in infants
September 27th 2024A recent study presented at the American Academy of Pediatrics 2024 National Conference & Exhibition, sheds light on the connection between skin conditions and sleep disturbances in infants and toddlers, highlighting itchy skin as a significant factor, even in the absence of atopic
Recognize & Refer: Hemangiomas in pediatrics
July 17th 2019Contemporary Pediatrics sits down exclusively with Sheila Fallon Friedlander, MD, a professor dermatology and pediatrics, to discuss the one key condition for which she believes community pediatricians should be especially aware-hemangiomas.